These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27955829)

  • 1. Open letter on access to the BIA 10-2474 clinical trial data.
    Brøsen K; Funck-Brentano C; Kroemer HK; Pirmohamed M; Schwab M
    Lancet; 2017 Jan; 389(10065):156. PubMed ID: 27955829
    [No Abstract]   [Full Text] [Related]  

  • 2. Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute-Bristol-Myers Squibb Supporting Open Access to Researchers Initiative.
    Pencina MJ; Louzao DM; McCourt BJ; Adams MR; Tayyabkhan RH; Ronco P; Peterson ED
    Am Heart J; 2016 Feb; 172():64-9. PubMed ID: 26856217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from the fatal French study BIA-10-2474.
    Moore N
    BMJ; 2016 May; 353():i2727. PubMed ID: 27193592
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: Fatal French Clinical Trial: What Can We Learn from What Went Wrong?
    Skaper SD
    CNS Neurol Disord Drug Targets; 2016; 15(7):752-3. PubMed ID: 27549166
    [No Abstract]   [Full Text] [Related]  

  • 5. [Not Available].
    Funck-Brentano C; Ménard J
    Presse Med; 2016 Sep; 45(9):719-22. PubMed ID: 27666586
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.
    Rocha JF; Santos A; Gama H; Moser P; Falcão A; Pressman P; Wallace Hayes A; Soares-da-Silva P
    Clin Pharmacol Ther; 2022 Feb; 111(2):391-403. PubMed ID: 33998672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGN-1412 and BIA-2474 Trials with Tragic End: Lessons Learnt To Make Clinical Trials Safer.
    Kaur RJ; Singh S; Sidhu P; Sharma PK
    Rev Recent Clin Trials; 2018; 13(4):252-256. PubMed ID: 29779485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of the BIA-102474-101 study for review of first-into-human clinical trials.
    Eddleston M; Cohen AF; Webb DJ
    Br J Clin Pharmacol; 2016 Apr; 81(4):582-6. PubMed ID: 26996741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical issues in first-in-human studies on BIA 10-2474: Neglected comparison of protocol against practice.
    Bird SM; Bailey RA; Grieve AP; Senn S
    Pharm Stat; 2017 Mar; 16(2):100-106. PubMed ID: 28206702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational proteome-wide screening predicts neurotoxic drug-protein interactome for the investigational analgesic BIA 10-2474.
    Molinski SV; Shahani VM; MacKinnon SS; Morayniss LD; Laforet M; Woollard G; Kurji N; Sanchez CG; Wodak SJ; Windemuth A
    Biochem Biophys Res Commun; 2017 Jan; 483(1):502-508. PubMed ID: 28007597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open clinical trials.
    Drazen JM; Morrissey S; Curfman GD
    N Engl J Med; 2007 Oct; 357(17):1756-7. PubMed ID: 17914035
    [No Abstract]   [Full Text] [Related]  

  • 12. More transparency for clinical trial data: The decision by the European Medicines Agency to make clinical trial reports publicly available could provide a boon for biomedical research.
    Hunter P
    EMBO Rep; 2015 Jan; 16(1):21-3. PubMed ID: 25476710
    [No Abstract]   [Full Text] [Related]  

  • 13. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.
    van Esbroeck ACM; Janssen APA; Cognetta AB; Ogasawara D; Shpak G; van der Kroeg M; Kantae V; Baggelaar MP; de Vrij FMS; Deng H; Allarà M; Fezza F; Lin Z; van der Wel T; Soethoudt M; Mock ED; den Dulk H; Baak IL; Florea BI; Hendriks G; De Petrocellis L; Overkleeft HS; Hankemeier T; De Zeeuw CI; Di Marzo V; Maccarrone M; Cravatt BF; Kushner SA; van der Stelt M
    Science; 2017 Jun; 356(6342):1084-1087. PubMed ID: 28596366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Pain: The Need and Hope for Opioid Alternatives.
    EBioMedicine; 2016 Mar; 5():1. PubMed ID: 27077094
    [No Abstract]   [Full Text] [Related]  

  • 15. NICE is urged to make drug companies supply all trial data.
    O'Dowd A
    BMJ; 2012 Dec; 345():e8294. PubMed ID: 23223692
    [No Abstract]   [Full Text] [Related]  

  • 16. [Public access to the results of clinical trials with drugs: is this enough for practicing physicians and patients?].
    Dal-Ré R
    Med Clin (Barc); 2014 Aug; 143(4):180-4. PubMed ID: 24667112
    [No Abstract]   [Full Text] [Related]  

  • 17. Take Care of the Fast-in-Human Study.
    van Hoogdalem EJ
    Clin Transl Sci; 2017 May; 10(3):122-123. PubMed ID: 27981812
    [No Abstract]   [Full Text] [Related]  

  • 18. Prime minister gives backing to more transparent drug trial data.
    O'Dowd A
    BMJ; 2012 Dec; 345():e8333. PubMed ID: 23220505
    [No Abstract]   [Full Text] [Related]  

  • 19. Making clinical data widely available.
    Kaiser J
    Science; 2008 Oct; 322(5899):217-8. PubMed ID: 18845745
    [No Abstract]   [Full Text] [Related]  

  • 20. US group suggests way to boost access to trial data while preventing misuse.
    Mayor S
    BMJ; 2013 Oct; 347():f6389. PubMed ID: 24150681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.